Amgen boosted by EPO hearing

Shares of Transkaryotic Therapies (TKTX) closed Wednesday at $53, down $25.125 (32 percent) on the week, after a U.S. District Court judge adopted modified versions of Amgen's definitions of four patent claim terms related to AGMN's erythropoietin patent infringement suit against TKTX and partner Aventis Pharmaceuticals.

Judge William

Read the full 483 word article

How to gain access

Continue reading with a
two-week free trial.